Accessibility Menu
Compugen logo

Compugen(NASDAQ) CGEN

Current Price$2.30
Market Cap$221.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-79%
5 Year-65%
1 Year+49%
1 Month+16%
Compugen last closing stock price
MetricPriceDate
Last closeUSD 2.342026-07-23
Compugen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.43%USD 2.332026-07-16
1 month+15.84%USD 2.022026-06-23
3 month-24.52%USD 3.102026-04-24
Year to date+52.94%USD 1.532025-12-31
1 year+49.04%USD 1.572025-07-23
3 year+108.93%USD 1.122023-07-24
5 year-64.92%USD 6.672021-07-23
Since inception-78.97%USD 11.132000-08-11

Compugen Financials at a Glance

Market Cap

$221.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$72.66M

Net Income (TTM)

$34.86M

EPS (TTM)

$0.37

P/E Ratio

6.39

Dividend

$0.00

Beta (Volatility)

1.66 (High)

Price

$2.30

Volume

3,335

Open

$2.35

Previous Close

$2.34

Daily Range

$2.28 - $2.35

52-Week Range

$1.30 - $3.24

Estimated Earnings Date

Aug 5, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Compugen

Compugen Ltd. is a clinical-stage biotechnology company based in Israel, focused on the discovery and development of innovative immuno-oncology therapies. Established in 1993, the company operates across Israel, the United States, and Europe, with a robust pipeline of investigational treatments targeting various solid tumors.

Products and Services
  • COM701: An anti-PVRIG antibody in Phase I trials for solid tumors
  • COM902: A therapeutic antibody targeting TIGIT, also in Phase I clinical studies
  • Bapotulimab: An antibody targeting ILDR2, currently in Phase I development
Growth Outlook
  • Strong pipeline with multiple candidates in clinical trials, enhancing future revenue potential
  • Strategic partnerships with industry leaders like Bayer and Bristol-Myers Squibb
  • Focus on myeloid targets may lead to innovative treatment options in immuno-oncology
Financial Highlights
  • Recent quarterly revenue of $2.18 million, showing potential for growth
  • Trailing twelve months (TTM) net profit margin of 48%, indicating operational efficiency
  • Current ratio of 6.23, reflecting strong liquidity position
Compugen Ltd. is positioned in the biotechnology sector, specifically within immuno-oncology, which is a rapidly growing field. The company’s focus on innovative therapies, combined with its strategic partnerships, enhances its potential for future growth. Recent financial data indicates a solid liquidity position and operational efficiency, which may attract potential investors looking for opportunities in the biotechnology space. The ongoing clinical trials and collaborations with established pharmaceutical companies further strengthen the company's market position and prospects for success.
AI Generated • Jul 21, 2026

Industry

Biotechnology

Employees

75

CEO

Eran Ophir, PhD

Headquarters

Holon, TA 5885849, IL

CGEN Financials

Key Financial Metrics (TTM)

Gross Margin

88.06%

Operating Margin

42.26%

Net Income Margin

47.97%

Return on Equity

47.72%

Return on Capital

29.64%

Return on Assets

23.90%

Earnings Yield

15.65%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$221.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

94.55M

Volume

3.33K

Avg. Volume

443.88K

Financials (TTM)

Gross Profit

$63.98M

Operating Income

$30.70M

EBITDA

$34.88M

Operating Cash Flow

$0.00

Capital Expenditure

$0.00

Free Cash Flow

$0.00

Cash & ST Invst.

$134.95M

Total Debt

$2.93M

Compugen Performance Analysis

Compugen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 7,500,00025.0%
20232023-12-31USD 33,459,000346.1%
20242024-12-31USD 27,864,000-16.7%
20252025-12-31USD 72,764,000161.1%
Compugen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-45.0%
Q32025-09-3050.4%
Q42025-12-313460.7%
Q12026-03-31-96.8%
Compugen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.39-4.2%
20232023-12-31USD -0.21-45.0%
20242024-12-31USD -0.16-25.7%
20252025-12-31USD 0.38N/A
Compugen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-0.9%
Q32025-09-305.0%
Q42025-12-31904.3%
Q12026-03-31-113.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.18M

-4.7%

Gross Profit

$352.00K

+403.4%

Gross Margin

16.18%

N/A

Market Cap

$221.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.95M

N/A

Employees

75

N/A

Net Income

-$7.67M

-6.8%

EBITDA

-$7.66M

-7.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$134.95M

+30.1%

Total Debt

$2.93M

+5.8%

Accounts Receivable

$2.34M

-25.7%

Inventory

$0.00

N/A

Long Term Debt

$2.37M

+1.1%

Short Term Debt

$559.00K

+32.2%

Return on Assets

23.90%

N/A

Return on Invested Capital

24.80%

N/A

Free Cash Flow

$0.00

N/A

Operating Cash Flow

$0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IPHAInnate Pharma S.A.
$1.83+3.69%
TNXPTonix Pharmaceuticals Holding Corp.
$10.24-3.63%
MOLNMolecular Partners AG
$3.96-0.25%
CRBPCorbus Pharmaceuticals Holdings, Inc.
$9.12-2.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.30-0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$64.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$44.16+0.02%
CLFCleveland-Cliffs
$11.05+0.01%

Questions About CGEN

What is the current price of Compugen?

Compugen is trading at $2.30 per share.

What is the 52-week range for Compugen?

Over the past 52 weeks, Compugen has traded between $1.30 and $3.24.

How much debt does Compugen have?

As of the most recent reporting period, Compugen reported total debt of $2.93M.

How much cash does Compugen have on hand?

Compugen reported $12.44M in cash and cash equivalents in its most recent financial results.

What is Compugen’s dividend yield?

Compugen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.